How to buy Chiasma stock - 11 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Chiasma stock

Own Chiasma stock in just a few minutes.

Chiasma, Inc is a biotechnology business based in the US. Chiasma shares (CHMA) are listed on the NASDAQ and all prices are listed in US Dollars. Chiasma employs 85 staff and has a trailing 12-month revenue of around USD$1.1 million.

How to buy shares in Chiasma

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Chiasma. Find the stock by name or ticker symbol: CHMA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Chiasma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Chiasma, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Chiasma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Chiasma share price

Use our graph to track the performance of CHMA stocks over time.

Chiasma shares at a glance

Information last updated 2021-04-08.
52-week rangeUSD$2.77 - USD$7.75
50-day moving average USD$3.45
200-day moving average USD$4.0089
Wall St. target priceUSD$13.6
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.227

Buy Chiasma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Chiasma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Chiasma financials

Revenue TTM USD$1.1 million
Gross profit TTM USD$1 million
Return on assets TTM -32.09%
Return on equity TTM -84.23%
Profit margin 0%
Book value $1.588
Market capitalisation USD$175.6 million

TTM: trailing 12 months

Shorting Chiasma shares

There are currently 2.9 million Chiasma shares held short by investors – that's known as Chiasma's "short interest". This figure is 7% up from 2.7 million last month.

There are a few different ways that this level of interest in shorting Chiasma shares can be evaluated.

Chiasma's "short interest ratio" (SIR)

Chiasma's "short interest ratio" (SIR) is the quantity of Chiasma shares currently shorted divided by the average quantity of Chiasma shares traded daily (recently around 1.8 million). Chiasma's SIR currently stands at 1.63. In other words for every 100,000 Chiasma shares traded daily on the market, roughly 1630 shares are currently held short.

However Chiasma's short interest can also be evaluated against the total number of Chiasma shares, or, against the total number of tradable Chiasma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Chiasma's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Chiasma shares in existence, roughly 50 shares are currently held short) or 0.0564% of the tradable shares (for every 100,000 tradable Chiasma shares, roughly 56 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Chiasma.

Find out more about how you can short Chiasma stock.

Chiasma share dividends

We're not expecting Chiasma to pay a dividend over the next 12 months.

Chiasma share price volatility

Over the last 12 months, Chiasma's shares have ranged in value from as little as $2.77 up to $7.75. A popular way to gauge a stock's volatility is its "beta".

CHMA.US volatility(beta: 1.38)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Chiasma's is 1.3806. This would suggest that Chiasma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Chiasma overview

Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site